Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Intervalo de año de publicación
1.
Obstet. gynecol ; 142(6)20231201. tab
Artículo en Inglés | BIGG - guías GRADE | ID: biblio-1525005

RESUMEN

To provide recommendations for the management of premenstrual syndrome and premenstrual dysphoric disorder, collectively referred to as premenstrual disorders, based on assessment of the evidence regarding the safety and efficacy of available treatment options. An overview of the epidemiology, pathophysiology, and diagnosis of premenstrual disorders also is included to provide readers with relevant background information and context for the clinical recommendations.


Asunto(s)
Humanos , Femenino , Adolescente , Adulto , Terapia de Reemplazo de Hormonas , Trastorno Disfórico Premenstrual/tratamiento farmacológico , Trastorno Disfórico Premenstrual/diagnóstico
2.
Obstet. gynecol ; 142(5): 1266-1273, 20231101. tab
Artículo en Inglés | BIGG - guías GRADE | ID: biblio-1525003

RESUMEN

Many compounding pharmacies use the phrase "bioidentical hormone" as a marketing term to imply that these preparations are natural and, thus, safer and more effective than U.S. Food and Drug Administration (FDA)­approved menopausal medications that use bioidentical or synthetic hormones or both. However, evidence to support marketing claims of safety and effectiveness is lacking. Compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. Clinicians should counsel patients that FDA-approved menopausal hormone therapies are recommended for the management of menopausal symptoms over compounded bioidentical menopausal hormone therapy. If a patient requests the use of compounded bioidentical menopausal hormone therapy, clinicians should educate them on the lack of FDA approval of these preparations and their potential risks and benefits, including the risks specific to compounding. To truly understand the benefits and harms of compounded bioidentical menopausal hormone therapy, high quality placebo-controlled randomized controlled trials with long-term follow-up comparing custom-compounded products with FDA-approved menopausal hormone therapy are needed.


Asunto(s)
Humanos , Menopausia , Terapia de Reemplazo de Hormonas , Publicidad Directa al Consumidor
3.
Obstet. gynecol ; 139(5): 944-972, 20220501.
Artículo en Inglés | BIGG - guías GRADE | ID: biblio-1372814

RESUMEN

To provide updated evidence-based recommendations for the evaluation and treatment of primary and secondary headaches in pregnancy and postpartum. Pregnant and postpartum patients with a history of or experiencing primary or new secondary headaches. This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Obstetrics and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements. This Clinical Practice Guideline includes recommendations on interventions to prevent primary headache in individuals who are pregnant or attempting to become pregnant, postpartum, or breastfeeding; evaluation for symptomatic patients presenting with primary and secondary headaches during pregnancy; and treatment options for primary and secondary headaches during pregnancy and lactation. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.


Asunto(s)
Humanos , Femenino , Embarazo , Periodo Posparto , Cefaleas Primarias/tratamiento farmacológico , Manejo del Dolor
5.
Recurso de Internet en Inglés | LIS - Localizador de Información en Salud | ID: lis-30359

RESUMEN

Ofrece información sobre el Colegio, sus autoridades, estructura y servicios. Provee acceso a materiales para educación continua de sus miembros y para sus pacientes, a sus publicaciones oficiales, a una libreria virtual, una agenda de eventos y un directorio de profesionales. Algunos materiales están disponibles en español


Asunto(s)
Folleto Informativo para Pacientes , Educación Médica Continua , Anticoncepción , Embarazo , Menopausia , Obstetricia , Ginecología , Sociedades Médicas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA